Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin.

Literature DB >> 22720223

Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin.

Ruben Hernandez-Alcoceba¹, Pedro Berraondo.

Abstract

Using a murine model of liver metastases, we found that oxaliplatin can enhance the immunostimulatory effect of interleukin-12 delivered by an adenoviral vector. A shift toward a favorable immune microenvironment was observed in tumors, with a relative increase in CD8+ T cells vs. T regulatory and myeloid-derived suppressor cells.

Entities: Chemical Disease Species

Year: 2012 PMID： 22720223 PMCID： PMC3376956 DOI： 10.4161/onci.1.1.17930

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

Review 1. Interleukin-12: biological properties and clinical application.

Authors: Michele Del Vecchio; Emilio Bajetta; Stefania Canova; Michael T Lotze; Amy Wesa; Giorgio Parmiani; Andrea Anichini
Journal: Clin Cancer Res Date: 2007-08-15 Impact factor: 12.531

2. Immunogenic death of colon cancer cells treated with oxaliplatin.

Authors: A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer
Journal: Oncogene Date: 2009-11-02 Impact factor: 9.867

3. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

Authors: Julie Vincent; Grégoire Mignot; Fanny Chalmin; Sylvain Ladoire; Mélanie Bruchard; Angélique Chevriaux; François Martin; Lionel Apetoh; Cédric Rébé; François Ghiringhelli
Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701

4. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.

Authors: N Morral; W O'Neal; K Rice; M Leland; J Kaplan; P A Piedra; H Zhou; R J Parks; R Velji; E Aguilar-Córdova; S Wadsworth; F L Graham; S Kochanek; K D Carey; A L Beaudet
Journal: Proc Natl Acad Sci U S A Date: 1999-10-26 Impact factor: 11.205

5. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.

Authors: Eiji Suzuki; Veena Kapoor; Arminder Singh Jassar; Larry R Kaiser; Steven M Albelda
Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531

6. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

Authors: Manuela Gonzalez-Aparicio; Pilar Alzuguren; Itsaso Mauleon; Jose Medina-Echeverz; Sandra Hervas-Stubbs; Uxua Mancheno; Pedro Berraondo; Julien Crettaz; Gloria Gonzalez-Aseguinolaza; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal: Gut Date: 2010-09-20 Impact factor: 23.059

7. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo.

Authors: M Reboredo; M Zabala; I Mauleon; J De Las Rivas; F Kreppel; S Kochanek; J Prieto; R Hernandez-Alcoceba; M G Kramer
Journal: Gene Ther Date: 2007-11-22 Impact factor: 5.250

Review 8. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.

Authors: Lionel Apetoh; Antoine Tesniere; François Ghiringhelli; Guido Kroemer; Laurence Zitvogel
Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701

9. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer.

Authors: Lin Wang; Rubén Hernández-Alcoceba; Vijay Shankar; Maider Zabala; Stefan Kochanek; Bruno Sangro; M Gabriela Kramer; Jesus Prieto; Cheng Qian
Journal: Gastroenterology Date: 2004-01 Impact factor: 22.682

Review 10. Myeloid-derived suppressor cells as regulators of the immune system.

Authors: Dmitry I Gabrilovich; Srinivas Nagaraj
Journal: Nat Rev Immunol Date: 2009-03 Impact factor: 53.106

10 in total

6 in total

Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin.

Review 1. Interleukin-12: biological properties and clinical application.

2. Immunogenic death of colon cancer cells treated with oxaliplatin.

3. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

4. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.

5. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.

6. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

7. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo.

Review 8. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.

9. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer.

Review 10. Myeloid-derived suppressor cells as regulators of the immune system.

1. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors.

2. An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.

3. Trial watch: DNA vaccines for cancer therapy.

4. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.

Review 5. Trial Watch: DNA vaccines for cancer therapy.

6. Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.